Canntab had originally announced that Latowsky would be appointed to the board as executive chairman, however, the board of directors unanimously determined that he would be much more valuable to the company in a full-time role as CEO
Canntab Therapeutics Limited () (OTCQB CTABF) (FRA:TBF1.F), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has announced the appointment of Larry Latowsky as its CEO effective immediately.
Originally appointed as an advisor to the company, Canntab said it has been mutually decided that Latowsky's extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the group’s operations and accordingly the board of directors decided to appoint him as CEO.
READ: Canntab Therapeutics eyeing sales of its hard pills this summer as it strikes purchase deal with MediPharm Labs
Canntab had originally announced that Latowsky would be appointed to the board as executive chairman, however, the board of directors unanimously determined that he would be much more valuable to the company in a full-time role as CEO to navigate Canntab's future growth.
It said Jeff Renwick, co-founder of Canntab, will assume the role of president and Head of Manufacturing while remaining an integral member of Canntab's board of directors.
Latowsky has held a number of leadership positions throughout his career including being president and CEO of Drug Trading Company and president and CEO of Katz Group Canada overseeing the largest network of pharmacy retailers in Canada operating as Rexall, Pharmaplus, IDA and Guardian Drugstores.
He also led Propharm Technology and DC Labs a vertical manufacturing and packaging division of pharmaceuticals and over the counter drug store product.
The group noted that Latowsky's experience is a unique blend of traditional retail bricks and mortar, distribution, manufacturing and e commerce/internet-based marketing and sales.
Commenting on his appointment, Latowsky said: "I am very excited to join Canntab on a full-time basis. Canntab's IP and product offerings are truly unique. Jeff Renwick and his production team's knowledge and experience in the production of pharmaceutical products is very impressive.
“There is a tremendous opportunity for Canntab's products both within Canada and worldwide. I would like to thank Jeff Renwick, Richard Goldstein and the entire Canntab board of directors for trusting me with this important role. I have no doubt that together we will continue to build a successful business which will benefit all of our shareholders"
Renwick added: "Making room for a person of Larry's experience was an easy decision. Our commitment is to build a world-class company and that begins by attracting world-class talent. We decided after working closely with Larry that his experience would be best suited to a daily role leading our company, especially in the crucial areas of sales, marketing and distribution with the tremendous growth opportunities which lie ahead.”
Canntab is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. It holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.
Additionally, Canntab through its wholly-owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in the United States.
Contact the author at [email protected]
